Obesity & Weight Management

SELECT Kidney Outcomes

Secondary analysis of the SELECT trial finds once-weekly semaglutide 2.4 mg modestly lowered a composite kidney endpoint versus placebo in adults with overweight or obesity and cardiovascular disease but no diabetes. PICO summary and expert commentary.

STEP-HFpEF

Prespecified pooled analysis of the STEP-HFpEF program: once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.

STEP 1-4 Trials: Semaglutide 2.4 mg for Weight Loss and Quality of Life

SELECT Trial: Long-Term Weight Loss with Semaglutide in Cardiovascular Disease

STEP-HFpEF: Semaglutide Improves NYHA Functional Class in Obesity-Related HFpEF

STEP-HFpEF NT-proBNP Analysis: Greater Benefit with Higher Baseline Cardiac Stress

STEP-HFpEF Pooled Analysis: Semaglutide Improves Symptoms, Function, and Inflammation in Obesity-HFpEF

Semaglutide and Obesity-Related Heart Failure

Tirzepatide Phase 1 Trial

A phase 1 clamp trial shows tirzepatide improves beta-cell function and insulin sensitivity more than semaglutide, explaining its glucose-lowering. PICO summary and commentary.

Semaglutide vs Canagliflozin for Body Composition in T2D: Fat Loss Similar Despite Greater Weight Loss with GLP-1 RA